The trade body for the UK’s pharma industry has added three new companies to its list of members.
The Association of the British Pharmaceutical Indsitry (ABPI) said that ALK- Abell and Shionogi have joined its ranks as full members, while Randox has become a research affiliate.
ALK- Abello is a specialist biopharma company, which is focused on the development of treatments for people with allergies.
This includes Pharmalgen, which was recommended in Europe last year as a treatment option for bee and wasp allergy.
Shionogi is a Japan-based pharma firm that is perhaps best known for discovering the blockbuster statin Crestor (rosuvostatin). The company was recently featured in PMLiVE’s emerging companies series.
The final new member Randox is a diagnostic solutions company that works with works with pharma and research organisations in the development of companion diagnostics.
“I’m delighted to welcome three new research led companies to the ABPI,” said the body’s CEO Stephen Whitehead.
“The industry is experiencing tremendous change and it is an important time for our members while we strive to improve levels of medicines uptake in the UK and as we engage in pricing negotiations with the Department of Health.”